Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
ERAD Chimeras: Targeted Degradation of Transmembrane Protein
2026-06-15
Song et al. introduce ERAD-engaging chimeras (ERADECs), a novel small-molecule platform that enables selective and efficient degradation of transmembrane proteins via the ER-associated degradation (ERAD) pathway. This approach overcomes major limitations of previous targeted protein degradation technologies and holds significant promise for drug discovery, particularly for membrane-bound targets.
-
CHIR 99021 Trihydrochloride: Redefining Organoid Precision
2026-06-15
Explore how CHIR 99021 trihydrochloride, a selective GSK-3 inhibitor, is transforming translational research by unlocking tunable control over stem cell fate, organoid diversity, and disease modeling. This article blends mechanistic insight with strategic guidance for researchers seeking to bridge experimental rigor and clinical relevance.
-
BI 2536: Precision PLK1 Inhibition for Functional Cancer Ass
2026-06-14
Discover how BI 2536, a selective PLK1 inhibitor, empowers advanced cancer research through precise control of cell cycle arrest and apoptosis. This article reveals practical assay strategies and novel insights for optimizing drug response evaluation.
-
CHIR 99021 Trihydrochloride: Unlocking Organoid Diversity vi
2026-06-13
Explore how CHIR 99021 trihydrochloride, a potent GSK-3 inhibitor, enables unprecedented control of stem cell self-renewal and differentiation in organoid systems. This in-depth article reveals new insights into balancing proliferation and cellular diversity for high-throughput biomedical research.
-
CDK9 Inhibitor (A3294): Technical Guidance and Workflow Use
2026-06-12
CDK9 inhibitor (A3294) is a selective serine/threonine kinase inhibitor designed for precise modulation of CDK9 activity in studies of transcription elongation and HIV-1 propagation. It is not appropriate for protocols requiring broad-spectrum CDK inhibition or long-term storage of working solutions.
-
Live-Dead Cell Staining Kit: Optimizing Calcein-AM PI Workfl
2026-06-12
The Live-Dead Cell Staining Kit empowers researchers with rapid, dual-fluorescent discrimination of viable and non-viable cells. Its superior accuracy and workflow flexibility make it indispensable for cell viability assays, drug cytotoxicity studies, and advanced biomaterial testing.
-
AM 281 and CB1 Signaling: Unlocking Astrocyte Modulation in
2026-06-11
Explore how AM 281, a potent CB1 cannabinoid receptor antagonist, advances research on astrocyte-mediated neuroprotection after traumatic brain injury. This article uniquely focuses on astrocytic glutamate homeostasis and translational assay implications.
-
Cefazedone (Refosporen): Translational Pharmacology & Advanc
2026-06-11
Explore the translational pharmacology of Cefazedone (Refosporen), a first-generation cephalosporin, and discover advanced, evidence-based assay strategies for both in vitro and in vivo research. This article uniquely bridges pharmacokinetic insight with practical experimental protocols.
-
ERAD-Hijacking Chimeras Enable Degradation of Transmembrane
2026-06-10
Song et al. introduce a novel platform—ERAD-engaging chimeras (ERADECs)—that harnesses the ER-associated degradation pathway for selective elimination of transmembrane proteins, overcoming a longstanding challenge in targeted protein degradation. This strategy demonstrates sub-nanomolar efficacy against PD-L1 and robust tumor suppression, offering a new paradigm for drug discovery targeting membrane proteins.
-
Resiniferatoxin (RTX): Precision TRPV1 Inactivation for Pain
2026-06-10
Resiniferatoxin (RTX) is an ultra-potent TRPV1 agonist enabling long-lasting chemical inactivation of sensory neurons. RTX achieves analgesia by sustained TRPV1 opening and Ca2+ influx, with efficacy 500–1000 times greater than capsaicin. Clinical and preclinical studies support RTX as a unique analgesic agent for osteoarthritis and neuropathic pain.
-
OLIG2 Modifications Control Glioma Invasion via TGF-β Pathwa
2026-06-09
This study reveals how post-translational modifications of the CNS transcription factor OLIG2 dictate the switch between proliferation and invasion in glioblastoma cells by modulating TGF-β2 expression and signaling. These findings identify TGF-β pathway modulation as a promising avenue for limiting glioma invasiveness and highlight new experimental strategies for dissecting tumor cell plasticity.
-
Canagliflozin: SGLT2 Inhibitor Workflows in Renal Research
2026-06-09
Canagliflozin enables precise SGLT2 inhibition while uniquely remodeling mitochondrial dynamics in diabetic kidney disease models. Discover actionable workflows, data-driven protocol refinements, and troubleshooting tips that advance both metabolic and renal research.
-
Precision RNA Purification: Empowering Translational Antivir
2026-06-08
This thought-leadership article explores how the APExBIO RNA Clean and Concentrator Kit advances the rigor and translational power of RNA virus research. We blend mechanistic insight from Senecavirus A (SVA) studies with guidance for optimizing RNA purification from enzymatic reactions, highlighting how researchers can elevate experimental reproducibility and strategic readiness for therapeutic innovation.
-
Isoprenaline Hydrochloride: Bridging Cardiac Models and Neur
2026-06-08
Explore how Isoprenaline Hydrochloride enables rigorous research into cardiac arrhythmia and heart-brain axis mechanisms. This article provides advanced scientific context and practical assay guidance, offering a unique perspective on isoproterenol’s translational applications.
-
Applied Workflows Using the Enhanced ECL Chemiluminescent Su
2026-06-07
The ECL Chemiluminescent Substrate Detection Kit (Enhanced) delivers ultra-sensitive western blot chemiluminescence detection and robust signal longevity, making it ideal for low-abundance protein studies and advanced oncology research. This article unpacks real-world workflows, protocol optimizations, and troubleshooting tactics that maximize assay reliability and reproducibility.